Valneva Austria Gmbh

Intercell Ag

Intercell Austria Ag

Markus Hanner

Andreas Meinke

Eszter Nagy

Urban Lundberg

Benjamin Wizel

Pär Comstedt

Wolfgang Schüler

Alexander Von Gabain

Ulrike Stierschneider

Markus Horky

Sabine Kallenda

Sonja Prustomersky

Jutta Pikalo

Birgit Noiges

Christina Satke

Robert Schlegl

Dieter Gelbmann

Christoph Reinisch

Manuel Zerbs

Astrid Teubenbacher

Sharmila Bakshi

Shailesh Dewasthaly

Thomas Cipps

Beatrice Senn

Brigitte Grohmann

Dagmar Zierer

Wolfgang Schueler

Beatrice Tschanun

Margarita Smidt

Carmen Giefing-Krōll

Carmen Giefing

Martin Oleksiewicz

Julia Bacher

Stefan Seidel

Michaela Weissgram

Sanja Selak

Par Comstedt

Wolfgang Schuler

Wolfgang SCHÜLER

The present invention relates to a polypeptide comprising a mutant fragment of an outer surface protein A (OspA), a nucleic acid coding the same, a pharmaceutical composition (particularly for use as a medicament of in a method of treating or preventing ainfection) comprising the polypeptide and/or the nucleic acid, a method of treating or preventing ainfection and a method of immunizing a subject.

Mutant fragments of OspA and methods and uses relating thereto

The present invention discloses isolated nucleic acid molecules encoding a hyperimmune serum reactive antigen or a fragment thereof as well as hyperimmune serum reactive antigens or fragments thereof from, and methods for isolating such antigens and specific uses thereof.

[object Object]

The present invention relates to an isolated nucleic acid molecule encoding an antigen, a vector comprising such nucleic acid molecule and a host cell comprising such vector. Furthermore, the invention provides antigens fromspecies, fragments and variants thereof, a process for producing such antigens, and a process for producing cells expressing such antigens. Moreover, the present invention provides antibodies binding to such antigen, hybridoma cells producing such antibodies, methods for producing such antibodies, a pharmaceutical composition comprising such nucleic acid molecule, antigen, vector or antibody, the use of such nucleic acid molecule, antigen, vector or antibody for the preparation of a pharmaceutical composition, methods for identifying an antagonist capable of binding such antigen or of inhibiting the interaction activity of such antigen, methods for diagnosis or for treatment or prevention of an infection. More specifically, such antigens are associated with nosocomial bacterial infections or infection by

The present invention relates to isolated nucleic acid molecules which encode an antigen from a nontypable() species, a vector which comprises such nucleic acid molecule, and a host cell comprising such vector. Furthermore, the invention provides antigens from a nontypablespecies, as well as fragments and variants thereof, a process for producing such antigens, and a process for producing a cell, which expresses such antigen. More specifically such antigens are produced by or associated with bacterial infections caused by nontypable. Moreover, the present invention provides antibodies binding to such antigen, a hybridoma cell producing such antibodies, methods for producing such antibodies, a pharmaceutical composition comprising such nucleic acid molecule, antigen, vector or antibody, the use of such nucleic acid molecule, antigen, vector or antibody for the preparation of a pharmaceutical composition, methods for identifying an antagonist capable of binding such antigen or of reducing or inhibiting the interaction activity of such antigen, methods for diagnosing an infection with nontypableand methods for the treatment or prevention of an infection with nontypable

The present invention discloses isolated nucleic acid molecules encoding a hyperimmune serum reactive antigen or a fragment thereof as well as hyperimmune serum reactive antigens or fragments thereof from, methods for isolating such antigens and specific uses thereof.

Enterococcus antigens

The present invention relates to a protective peptide of() or a functionally active variant thereof; a composition comprising at least two of such peptides or variants; one or more nucleic acid(s) encoding such peptide or variant; a pharmaceutical composition comprising such peptide or variant, composition, or nucleic acid(s); a method of producing an antibody using such peptide or variant or composition; the use of such peptide or variant and/or composition and/or nucleic acid(s) for the manufacture of a medicament; a method of diagnosing ainfection using such peptide or variant, composition or a primer and/or probe specific for the nucleic acid(s); a method for identifying a ligand capable of binding to such peptide or variant; and the use of such peptide or variant for the isolation, purification and/or identification of an interaction partner of the peptide.

Growing community of inventors

Pressbaum, Austria

Markus Hanner